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Summary
Objectives: To investigate the relative contribution of the cyclooxygenase (COX) isoenzymes COX-1 and COX-2 to prostaglandin E2 (PGE2)
release from inﬂamed synovial tissue in N ¼ 10 patients with primary osteoarthritis (OA) in vitro and to determine possible effects of COX
inhibitors on the gene expression of synovial COX-1 and COX-2.
Design: The effects of a COX-unspeciﬁc nonsteroidal anti-inﬂammatory drug (NSAID; diclofenac), a selective COX-1 inhibitor (SC-560) and
a selective COX-2 inhibitor (SC-58125) on PGE2 release from inﬂamed synovial tissue (0.1e10 mM, 3 and 6 h incubation time) were
compared. Release of PGE2 into the incubation media was measured by means of the enzyme-linked immunosorbent assay. Expression of
synovial COX-1/-2 was quantiﬁed by means of real-time reverse transcriptase polymerase chain reaction (RT-PCR).
Results: All agents inhibited synovial PGE2 release dose-dependently. Compared to short-term incubations, the inhibitory potency of
diclofenac, SC-58125 and SC-560 was increased (0.1e10 mM) and decreased (0.1e1 mM), respectively, during 6 h: At 10 mM, SC-560 and
SC-58125 had obviously lost their speciﬁcity for COX-1 and COX-2, respectively, indicated by a comparable inhibitory potency of the selective
COX-1 inhibitor (86.6%) and the selective COX-2 inhibitor (96.6%) within identical tissue specimens. In contrast, at 1 mM, 83% and 62.8%
inhibition was seen for diclofenac and SC-58125, respectively. SC-560 showed 30.6% inhibition (P!0:05). In contrast to synovial COX-1,
RT-PCR revealed a signiﬁcant induction of COX-2 through PGE2.
Conclusions: With respect to the concentrations studied, the data suggest that in inﬂamed synovial tissue in OA, up to 30% of PGE2 might be
generated via the COX-1 pathway. In therapy of OA, the relative contribution of COX-1 in synovial inﬂammation should be considered,
weighing the potency of COX-unspeciﬁc NSAID against the assumed superior gastrointestinal safety proﬁle of selective COX-2 inhibitors.
 2004 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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arthritis, RT, reverse transcription, SE, standard error, TNFa, tumor necrosis factor alpha.
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Apart from degeneration of articular cartilage and sclerosis
of the subchondral bone, inﬂammation of the synovial
membrane represents a key event in the pathophysiology of
osteoarthritis (OA): It is initiated and promoted by denatured
cartilage detritus captured in the synovial lining cells and
contributes to the clinical symptoms of OA like swelling,
pain and stiffness.1e3 The synovitis itself is characterized
by an activation of resident cells, synovial stroma and lining
synoviocytes due to an inﬂammatory inﬁltrate of lympho-
cytes and monocytes.4,5 Pro-inﬂammatory as well as anti-
inﬂammatory effects have been demonstrated for a variety
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Received 15 September 2003; accepted 3 May 2004.658of different mediators released from inﬂamed synovial
tissue in OA, among them cytokines, neuropeptides and
eicosanoids.6e8 Many of them have subsequent secondary
effects on extrasynovial cells like interleukin (IL)-1b-de-
pendent increase of proteinase release from chondrocytes
or a tumor necrosis factor alpha-dependent hypovascula-
rization of the subchondral bone.9,10
Regarding eicosanoid release in OA, cyclooxygenase
(COX)-1 and COX-2, two isoforms of the key enzyme in
prostaglandin (PG) synthesis11,12, are expressed in syno-
vitis tissue.13 Within the synovial membrane in OA, COX-2
is the predominantly expressed isoenzyme. Its strongest
expression is seen in the lining cells followed by blood
vessels and the sublining layer. COX-1 is likewise ex-
pressed in the corresponding synovial compartments
though to a lesser extent.14
COX-1 is regarded as the ‘‘housekeeping’’ isoform and is
constitutively expressed in healthy tissue like gastric mucosa
without any substantial induction through inﬂammatory
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inﬂammation.15,16 This fact has led to the development of
selective COX-2 inhibitors, featuring compounds like Rofe-
coxib, Celecoxib, Lumiracoxib, Etoricoxib, Valdecoxib or
Parecoxib. Their assumed superior gastrointestinal safety
proﬁle, however, is still controversial.17
In the treatment of OA, selective COX-2 inhibitors have
been demonstrated to be as effective as classical
COX-unspeciﬁc nonsteroidal anti-inﬂammatory drugs
(NSAID).18,19
The established concept that PG synthesis in inﬂamma-
tion is always COX-2-dependent, while COX-1ePG primar-
ily modulate the physiological homeostasis, has been
modiﬁed by investigations demonstrating a signiﬁcant
participation of PG derived via the COX-1 pathway in some
inﬂammatory processes.20e27
The purpose of this study was to compare the effects of
a COX-unspeciﬁc NSAID (diclofenac, Voltaren), a selec-
tive COX-1 inhibitor (SC-560) and a selective COX-2
inhibitor (SC-58125) on PGE2 release from inﬂamed
synovial tissue in primary OA in vitro in order to quantify
the relative contribution of COX-1 and COX-2. Furthermore,
the question whether SC-560 and SC-58125 would exhibit
possible effects on the synovial expression of the two COX
isoenzymes due to the inhibition of PGE2 synthesis was
addressed.
Material and methods
PATIENTS
Synovial tissue was obtained surgically from patients with
unsuccessful conservative treatment for primary OA of the
knee (N ¼ 10, 4 female, 6 male, average age 68 years,
range 55e76 years) during total knee replacement. At the
time of surgery, patients had been without NSAID therapy
for at least 14 days and without glucocorticoid therapy28 for
at least 4 weeks. None of the patients had previously
received intra-articular treatment with hyaluronic acid.29
HISTOLOGICAL ANALYSIS OF SYNOVIAL TISSUE (N ¼ 1e5)
Processing of synovial tissue
Specimens of synovial tissue were ﬁxed in 4% formalin,
dehydrated in graded concentrations of ethanol and
embedded in parafﬁn. Apart from hematoxylin and eosin
(HE) and Elastica-van-Gieson’s (EVG) staining, immuno-
histochemical stainings were performed to identify CD3
T-lymphocytes, CD20 B-lymphocytes and CD68 macro-
phages.
Immunohistochemistry
Parafﬁn-embedded sections were stained with mono-
clonal mouse-anti-human primary antibodies against CD3
(Novocastra clone PS1, dilution 1:50), CD20 (DAKO clone
L26, dilution 1:800) and CD68 (DAKO clone PG-M1,
dilution 1:400) to identify T-lymphocytes, B-lymphocytes
and macrophages, respectively. Sections (4 mm) were
deparafﬁnized in xylene and microwaved for 20 min in
EDTA-buffer ( pH 8.0) for antigen unmasking. After rinsing
in Tris-buffer ( pH 7.2; 5 min), sections were incubated with
the primary antibodies for 25 min, followed again by
rinsing with Tris-buffer. Primary antibody detection was
performed with DAKO kit k5005, including a secondary
biotinylated anti-mouse antibody, Tris-buffer and alkalinephosphatase-conjugated streptavidin complex. Neofuch-
sine was used as the chromogen and Mayer’s hematoxylin
as the counterstain.
Microscopic evaluation
The synovial inﬂammation was scored (none/mild/mild-
to-moderate/moderate/severe) by a pathologist who was
blinded to the patient’s history and the results of the
corresponding incubations. Furthermore, the inﬂammatory
cell types detected in the stained sections were evaluated
semiquantitatively (absent, C, CC, CCC).
The incubated synovial tissue (the incubation procedure
is described below) was also analyzed histologically (HE) to
ascertain that the investigated specimens exclusively
consisted of inﬂamed synovial tissue.
DETERMINATION OF SYNOVIAL PGE2 RELEASE (N ¼ 1e5)
Tissue preparation and incubation
Immediately after harvesting, synovial tissue was stored
in C4(C cold, sterile saline solution and transported to the
laboratory. Here, after removal of adherent tissue like fat
and muscle, the synovitis tissue was cut into small pieces of
approximately 2!2 mm on a cooled petri-dish, mixed,
introduced into vials in aliquots up to 50 mg wet weight
(w.w.) and rinsed three times with ice-cold Tyrode solution
to remove debris and blood. Thereafter the tissue was
incubated in pre-warmed (37(C) Tyrode solution in a CO2
thermal chamber in the presence of graded concentrations
(0.1, 1 and 10 mM) of diclofenac, SC-560 and SC-58125 for
3 h and 6 h, respectively.
Incubations were performed in pairs for every concen-
tration. Controls were incubated without drugs to determine
the basic PGE2 release. After 3 h the supernatants were
collected and stored at 20(C until further analysis. After
substitution of the corresponding buffer, the incubations
were continued for another 3 h. After a total of 6 h
incubation time, the supernatants were collected and again
stored at 20(C, while the incubated tissue specimens
were processed for histological examination.
ELISA
The amounts of PGE2 released into the incubation media
were measured using an enzyme-linked immunosorbent
assay (ELISA) kit (Cayman Chemicals, Ann Arbor, MI,
USA) according to the manufacturer’s instruction. Forma-
tion of synovial PGE2 was expressed as ng per g of tissue
wet weight (w.w). The effect of the investigated agents on
PGE2 release was calculated as % inhibition vs untreated
control (meansGstandard error, SE). Statistical analyses
were performed using Student’s test for matched pair data
with a P-value !0.05 considered signiﬁcant.28
Drugs
Diclofenac sodium was purchased from Sigma Chem-
icals Co (St Louis, MO, USA). SC-560 and SC-58125 were
purchased from Alexis Chemicals (Gruenberg, Germany).
Dimethyl sulfoxide (DMSO) and the chemicals for consti-
tuting the Tyrode buffer were purchased from Carl Roth
GmbH (Karlsruhe, Germany).
Diclofenac sodium was dissolved and diluted
(0.1e10 mM) in Tyrode solution. SC-560 and SC-58125
were dissolved in DMSO. For the incubation experiments,
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Sequences of primers and hybridization probes employed for the quantitative nested real-time RT-PCR for synovial COX-1
Oligonucleotide Sequence
COX-1 sense 5#-GTCCTCCCCTATTGCG-3#
COX-1 antisense 5#-ACTGTCAGACCGAACT-3#
COX-1 sensor 5#-CTTCATGATCCACACTTTGGGC-FL-3#
COX-1 anchor 5#LightCycler Red640-AGTATTTCTCAGGAAGAGCTATGGC-p-3#these stock solutions were diluted with Tyrode solution
containing DMSO to maintain constant DMSO concentra-
tions for all dilution steps.
QUANTITATIVE NESTED REAL-TIME REVERSE TRANSCRIPTASE
POLYMERASE CHAIN REACTION (RT-PCR) FOR SYNOVIAL COX-1
AND COX-2 TRANSCRIPTS (N ¼ 6e10)
Tissue preparation and incubation
Immediately after harvesting, 40 mg synovial tissue (of
another ﬁve patients with primary OA of the knee) was
stored in an RNA ﬁxation buffer (RNAlater, Qiagen, Hilden,
Germany) to preserve the in vivo pattern of gene expression
within the synovitis tissue. The tissue was stored at C4(C
for further RNA isolation (referred to as the ‘‘ex vivo’’
expression). To determine the in vitro expression, further
40 mg specimens of the dissected synovial tissue
( procedure as described above) were incubated for 6 h in
RPMI 1640 culture media (Biochrom AG, Berlin, Germany)
either without drugs or with 10 mM SC-560 and 10 mM
SC-58125, respectively. RPMI 1640 media contained 10%
fetal calf serum (FCS), 5% glutamine as well as 5%
penicillin/streptomycin.30 Stock solutions of SC-560 and
SC-58125 were diluted with the modiﬁed RPMI 1640 media
to achieve a ﬁnal concentration of 10 mM. DMSO was
added to the RPMI/FCS/glutamine/penicillin/streptomycin
solution to maintain constant DMSO concentrations in all
the investigated buffers. After the corresponding incubation
time, the supernatants were discarded and the synovial
tissue was immediately stored in RNAlater buffer (referred
to as the ‘‘in vitro’’ expression).
Isolation of RNA
Disruption and homogenization of the RNAlater stabilized
synovial tissue was performed using the Mixer Mill MM 300
(Qiagen) with 5 mm steel beads (Retsch, Haan, Germany).
Total RNA was isolated with the RNeasy isolation kit
(Qiagen) according to the manufacturer’s instruction. RNA
was resuspended in 30 ml H2O (RNase-free).
RT
Using the Promega Reverse Transcription system
(Promega, Madison, USA), 1 mg of total RNA was reverse
transcribed with 15 U AMV reverse transcriptase for 1 h at42(C in a total volume of 20 ml to obtain total cDNA. The
reaction was primed with 0.5 mg oligo-(dT)15 primers. The
enzyme was inactivated following the RT for 5 min at 95(C.
The cDNA was stored at 20(C until further processed
for PCR.
Real-time PCR
Ampliﬁcation of COX-1 and COX-2 was performed using
the LightCycler system in a total volume of 20 ml of
LightCyclereFastStart DNA Master Hybridization solution
(Roche Molecular Biochemicals, Mannheim, Germany)
containing 3.0 mM MgCl2, dNTP, and Taq DNA poly-
merase including 2 ml of cDNA and 0.5 mM primers COX-
1/-2 sense, COX-1/-2 antisense, and 0.2 mM of a nested
3#-ﬂuorescein-labeled sensor oligonucleotide. The PCR
mix also contained 0.2 mM of a 5#-LightCycler Red640-
labeled oligonucleotide anchor, phosphorylated at its
3# end (Tables I and II). PCR was initiated by incubating
the reaction mix for 10 min at 95(C. PCR was performed in
45 cycles of 10 s at 95(C (denaturation), 10 s at 54(C
(annealing), and 15 s at 72(C (extension) with online
detection of ﬂuorescence at the end of the annealing
phase. For quantiﬁcation of COX-1/-2 transcripts, human
porphobilinogen deaminase (h-PBGD) was chosen as
housekeeping gene (incubation media with and without
drugs proved to cause no change in h-PBGD expression)
and used as control for normalization of COX-1/-2
expression levels. Primers and hybridization probes were
contained in the LightCyclereh-PBGD housekeeping gene
set from Roche Molecular Biochemicals. Cycling conditions
were exactly as described for the ampliﬁcation of COX-1/-2
transcripts.
Relative quantification of COX-1/-2 mRNA
expression
For quantiﬁcation of COX-1/-2 transcript levels, the
amount of the COX-1/-2 transcript and that of h-PBGD
transcript were determined for each sample. Calculation of
the normalized ratios (NR) of COX-1 and COX-2/h-PBGD
was performed using the LightCycler Relative Quantiﬁca-
tion Software Version 1.0 (Roche) providing an additional
correction for differences in ampliﬁcation efﬁciency and
detection sensitivity (calibrator normalization) of the corre-
sponding PCR. A DNase digestion (Qiagen) was performed
already during RNA extraction to rule out an artiﬁcialTable II
Sequences of primers and hybridization probes employed for the quantitative nested real-time RT-PCR for synovial COX-2
Oligonucleotide Sequence
COX-2 sense 5#-TTCAAATGAGATTGTGGAAAAATTGCT-3#
COX-2 antisense 5#-TTCAAATGAGATTGTGGAAAAATTGCT-3#
COX-2 sensor 5#-TGGGCCATGGGGTGGACTTAAATCA-FL-3#
COX-2 anchor 5#LightCycler Red640-TTTACGGTGAAACTCTGGCTAGACAGCGTAAAC-p-3#
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primers and hybridization probes during the PCR. Further-
more, BLAST homology search31 revealed no secondary
priming sites. Again, statistical analyses were performed
using Student’s test for matched pair data with a P-value
!0.05 considered signiﬁcant.
Results
HISTOLOGICAL ANALYSIS OF SYNOVIAL TISSUE
In the fresh synovial tissue specimens, leucocytic
inﬁltrations consisting mainly of T-lymphocytes and
B-lymphocytes were present. The inﬂammatory inﬁltrates
were closely associated with synovial blood vessels.
Inclusions of cartilaginous residues were found adjacent
to the synovial surface, partly showing signs of organization
in the presence of macrophages and scattered giant cells
(Fig. 1 AeD, Table III). Furthermore, no foreign tissue like
fat or muscle was detectable in the incubated synovial
specimens.
SYNOVIAL PGE2 RELEASE
After 3 h and 6 h of incubation, synovitis tissue showed
a mean release of 329G106 ng PGE2/g w.w. and1024G314 ng PGE2/g w.w., respectively. After 3 h of
incubation (Fig. 2), all agents concentration-dependently
inhibited synovial PGE2 release. An inhibition ofO85% was
seen for 10 mM diclofenac (P!0:05) and 10 mM SC-560
(P!0:05), while 10 mM SC-58125 showed a maximum
inhibition of 52.6% (n.s.). During 6 h (Fig. 3) the inhibitory
potency of SC-560 and SC-58125/diclofenac was de-
creased and increased, respectively. All agents achieved
equipotent efﬁciency at 10 mM. At 1 mM, 83% and 62.8%
inhibition was seen for diclofenac and SC-58125, respec-
tively, while SC-560 showed 30.6% inhibition.
SYNOVIAL EXPRESSION OF COX-1/-2
RT-PCR conﬁrmed the expression of COX-1 and COX-2
in the investigated synovial tissue, both ex vivo and in vitro.
Compared to the expression ex vivo, unlike COX-1, the
expression of COX-2 was signiﬁcantly induced in vitro after
6 h of incubation without drugs (O10,000-fold, P!0:05,
Table IV). Reduced PGE2 synthesis due to the effect of
10 mM SC-560 and SC-58125 resulted in an increased
synovial COX-1 expression, though this effect was not
signiﬁcant (Fig. 4). In contrast, the expression of synovial
COX-2 was signiﬁcantly decreased (P!0:05, Fig. 5),
demonstrating a PGE2-dependent feed-forward loop.
The ampliﬁcation of the desired target sequences duringFig. 1. AeD: HE, EVG and immunohistochemical staining for CD3 T-lymphocytes, CD20 B-lymphocytes and CD68 macrophages in
representative synovial tissue sections (3 mM) from patients (N ¼ 1e5). Immunostaining was performed as described in Material and Methods.
(A) Synovial tissue with a perivascular, follicular B-lymphocyte inﬁltrate detected by anti-CD20 antibodies. (B) CD3-positive T-lymphocytes
surroundingsmall vessels adjacent to the synovial surface.Note the small cartilaginous residueseparatedbyagranulomadevoidofCD3-positive
cells (arrows). (C) Large fraction of intra-synovial cartilage surrounded and inﬁltrated by macrophages/chondroclasts stained with anti-CD68
antibodies. (D) Cartilaginous tissue fragment incorporated in the stratum synoviale showing a mild granulomatous reaction with EVG staining.
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Scoring of synovial inflammation
Patient (N ¼ 1e5) Synovitis CD3 T-lymphocytes CD20 B-lymphocytes CD68 macrophages Neutrophils Giant cells
1 Moderate CCC CCC C C C
2 Mild-to-moderate CC C C C C
3 Moderate CC CC C C C
4 Mild CC C C Absent Absent
5 Mild C C C Absent Absent
Immediately after harvesting, the synovial tissue was stored in 4% formalin to be further processed for histological examination. The
parafﬁn-embedded sections were stained with HE, EVG and immunohistochemically stained for CD3 T-lymphocytes, CD20 B-lymphocytes
and CD68 macrophages. Light microscopic evaluations were performed by a pathologist blinded to the patient’s history and the results of the
corresponding incubations. Synovitis was graded as either none, mild, mild-to-moderate, moderate or severe. The cell types detected in the
leucocytic inﬁltrates were semiquantitatively scored as either absent, C, CC or CCC.the PCR was conﬁrmed by agarose gel electrophoresis
(Fig. 6).
Discussion
When interpreting the effects of COX inhibitors in in vitro
studies, it must be remembered that selectivity is time- and
dose-dependent. Selective COX-2 inhibitors initially bind to
both COX isoenzymes reversibly, only the COX-2 binding
becomes irreversible time-dependently, providing a compar-
atively more potent inhibition.32e34 With respect to NSAID
like diclofenac, the initial binding to COX-1 and COX-2
changes into a functional irreversible one to both COX
isoenzymes.35
At concentrations R10 mMdwhich have been achieved
in plasma and synovial ﬂuid in vivo under continuous
NSAID therapy36,37dselective COX-2 inhibitors increas-
ingly co-inhibit COX-1 activity.35,38,39
Though detailed pharmaco-kinetic investigations still
remain to be performed, our data suggest a comparable
inﬂuence of incubation time and concentration on the
interaction of SC-560 and COX-1: After 3 h of incubation,
at 10 mM SC-560 showed an almost equal inhibition of
Fig. 2. Release of PGE2 fromsynovial tissue after 3 h of incubation in
the presence of 0.1e10 mM diclofenac, SC-560 and SC-58125.
Synovial PGE2 release into the corresponding tissue supernatants
(N ¼ 1e5) was measured by means of a commercial ELISA kit. The
effects of the investigated compounds were calculated as % inhi-
bition of PGE2 release compared to the release from the untreated
controls and are displayedasmeansGSE.Student’s test formatched
pair data was employed to verify the signiﬁcance (P!0:05) of this
effect. A dose-dependent inhibition was seen for all three agents.synovial PGE2 release (85.3%) as equimolar COX-
unspeciﬁc diclofenac (86.3%). Obviously, to some extent,
SC-560 (and/or SC-58125) did perform COX-unspeciﬁc
inhibition. This COX-unspeciﬁcity, in turn, might be a result
of two different phenomena.
Firstly, COX-unspeciﬁc inhibition might be due to
concentration-dependency: At 10 mM, SC-560 (and SC-
58125) might already have performed a co-inhibition of
synovial COX-2 and COX-1, respectively, due to a concen-
tration-dependent increase of COX-unspeciﬁcity. 35,38,39 On
the one hand, this hypothesis would be promoted by the
fact that during short-term incubations at the lower
concentration of 1 mM, 79.3% COX-1-dependent inhibition
of synovial PGE2 and 37.5% COX-2-dependent inhibition
would roughly add up to a total of 100% inhibition possible.
On the other hand, no data have been obtained so far,
supporting the idea that almost 80% of inﬂammatory PGE2
in OA could possibly be derived via the COX-1 pathway.
Thus, concentration-dependency alone seems to be a rather
unlikely explanation.
Secondly, COX-unspeciﬁc inhibition might be due to the
limitation of incubation time: After 3 h, SC-560 could have
possibly inhibited the activity of both COX-1 and COX-2, still
being captured in the state of time-dependent, reversible
binding to both COX isoenzymes. At 10 mM the selective
COX-2 inhibitor achieved only around 60% of equimolar
diclofenac’s efﬁciency. This might be due to not having left
the less potent state of COX-unspeciﬁc inhibition either.32e35
Fig. 3. Release of PGE2 from synovial tissue after 6 h of incubation
in the presence of 0.1e10 mM diclofenac, SC-560 and SC-58125.
Despite a dose-dependent inhibition, the inhibitory potency of
0.1e1 mM SC-560 had decreased compared to the short-term
incubations.
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unspeciﬁcity seen during the short-term incubations and to
elucidate the relevance of incubation time for the inhibitory
potency of SC-560 and SC-58125, the synovitis tissue was
incubated for another 3 h.
Compared to the short-term incubations, after a total of
6 h of incubation time, at the highest concentration of
10 mM, the potency of all agents had increased (SC-
58125OdiclofenacOSC-560). At 10 mM SC-560 and SC-
58125 had obviously lost the speciﬁcity for ‘‘their’’ COX
isoenzyme, indicated by an else impossible almost-equi-
potency of a selective COX-1 inhibitor (86.6%) and
a selective COX-2 inhibitor (96.6%) within identical synovial
tissue specimens. In sharp contrast to the data obtained at
10 mM, the 1 mM data reveal something completely differ-
ent: The inhibitory potency of SC-58125 had increased
compared to the short-term incubations ( from 51.8% to
Table IV
Synovial expression of COX-1 and COX-2 ex vivo and in the
untreated controls after 6 h in vitro
Synovial tissue
(N ¼ 6e10)
COX-1 expression
(normalized ratio)
COX-2 expression
(normalized ratio)
Ex vivo 0.17G0.02 0.047G 0.02
6 h In vitro 0.17G0.06 635G230*
To determine the synovial COX expression ex vivo, 40 mg of the
excised synovial tissue was immediately stored in RNAlater until
further processed for RNA extraction and RT-PCR. With respect to
the expression in vitro, another 40 mg of synovial tissue was
incubated for 6 h in modiﬁed RPMI 1640 media without drugs
(untreated control). The expression of COX-l and COX-2 in the
synovial tissue (N ¼ 6e10) was determined by means of real-time
RT-PCR and normalized against h-PBGD housekeeping gene to
calculate the normalized ratio (NR). COX-expression is expressed
as mean NRGSE. *Compared to the expression ex vivo, COX-2
was signiﬁcantly (P!0:05) induced in vitro.
Fig. 4. Secondary modulation of synovial COX-1 expression in the
presence of 10 mM SC-560 and SC-58125 compared to the
untreated controls due to the inhibitor’s effect on synovial PGE2
synthesis after 6 h of incubation (N ¼ 6e10). The relative
expression of COX-1 was determined as described in the Material
and Methods section and calculated as mean NRGSE. The
inhibitor’s effect on COX-1 expression was calculated and
displayed as -fold increase of expression (meansGSE) compared
to the untreated controls. Note that the increase of COX-1
expression did not reach signiﬁcance.71.8%), while in parallel, the inhibition caused by equimolar
SC-560 had dropped from 89.2% (3 h) to 30.6% (6 h). For
the investigated compounds, this inverse behavior charac-
terizes a shift from COX-unspeciﬁcity (10 mM) to COX-
selectivity (1 mM). Furthermore, by conﬁrming the basic
tenor of literature (with PGE2 release from OA synovitis
tissue supposed to be dominated by the COX-2 iso-
enzyme), the 1 mM data appear more reliable and valid for
drawing conclusions than the data obtained at 10 mM. In
summary, by decreasing the COX-unspeciﬁcity of the
selective inhibitors, the long-term incubations indicate that
at between 1 and 0.1 mM rather than between 1 mM and
10 mM, the selective inhibitors perform speciﬁc inhibition of
‘‘their’’ special COX-isoenzyme. Thus, COX-1 participation
in synovial PGE2 release in vitro is rather %30.6% than
R30.6%. It should, however, be noted that of all agents
studied, diclofenac showed the strongest inhibitory potency.
Even though COX-1 expression is not induced, its
enzymatic activity could still be stimulated through
increased levels of free arachidonic acid (AA), the precursor
substance for PG synthesis. The increased liberation of AA
out of its endogenous stores, in turn, is probably due to
a cytokine-dependent activation and induction of synovial
phospholipase A2.40e42 Since the model employed in our
study was intended to resemble the in vivo situation of
synovitis in OA as closely as possible, we investigated
synovial tissue ex vivo instead of isolated, synovial cells or
puriﬁed enzymes. In order to most possibly draw valid
conclusions from the in vitro data for the in vivo situation of
COX-1/-2 in synovitis tissue, no artiﬁcial stimulation was
applied. Furthermore, no secondary re-interpretation of the
initial ELISA/PCR data was performed, because of the
differences in relative cellular density of COX-1/-2 generat-
ing cells seen in the corresponding histologies.
In previous studies the expression of the two COX
isoenzymes in OA synovium has been demonstrated in
local cells like synoviocytes or blood vessel endothelium as
well as in immigrated leucocytes.13,14,21,43,47,48 With re-
spect to the cell types detected in osteoarthritic synovitis,
the histological analyses of the patient’s synovial tissue
Fig. 5. Secondary modulation of synovial COX-2 expression in the
presence of 10 mM SC-560 and SC-58125 compared to the
untreated controls due to the inhibitor’s effect on synovial PGE2
synthesis after 6 h of incubation (N ¼ 6e10). While the presence of
both agents resulted in a decreased expression of COX-2, this
effect was only signiﬁcant (P!0:05) for SC-58125.
664 H. Knorth et al.: Contribution of COX to PGE2 release in osteoarthritisFig. 6. (A) Representative time course of ﬂuorescence vs cycle number detected during 45 cycles of ampliﬁcation of COX-2 and housekeeping
gene h-PBGD in synovial tissue specimens after incubation with 10 mM SC-560 and SC-58125 for 6 h. The calibrator is required for calculating
the corresponding NR as described in Material and Methods. To keep the ﬁgure simple, ampliﬁcation curves of ex vivo tissue specimens and
untreated controls are not displayed. (B) Ethidium bromide staining of the corresponding PCR products separated in a 1% agarose gel.
According the molecular weight (base pairs, bp), the lanes show the ampliﬁed target sequence. From left to right: h-PBGD (150 bp), COX-1
(243 bp), COX-2 (305 bp) and a commercial, graded ladder (bp 100e1000).(N ¼ 1e5) conﬁrmed the data published in those studies:
Apart from leucocytic inﬁltrations and cartilage detritus,
proliferation and hyperplasia of the synovial lining cells as
well as an increased vascularization and edema of the
synovial stroma was present.13,14,43,44 The most severe
inﬂammatory changes in OA synovium had previously been
demonstrated in patients at the time of joint replacement
sugery.44,45 In compliance with this ﬁnding, lymphoid
aggregates which are regarded as one indication of
a comparatively pronounced synovial inﬂammation44 were
frequently detectable in our sections.
A signiﬁcant induction of COX-2 expression (O10,000-
fold) was seen within the incubated synovial tissue after 6 hof incubation, most likely due to the tissue dissection and the
incubation process itself.40 One would expect this COX-2
induction to increase the potency of the selective COX-2
inhibitor and diclofenac, rather than that of SC-560. Further-
more, this COX-2 induction may partly compensate for the
loss of COX-2 induction through synovial PGE2, due to the
inhibitory effects of SC-560 and SC-58125 on PGE2 gene-
ration. A PGE2-dependent feed-forward loop has already
been detected in IL-1b-stimulated synovial ﬁbroblasts.46
Furthermore, our data conﬁrm the results of Anderson and
co-workers, who found a decreased COX-2 expression due
to SC-58125 in inﬂamed paw tissue of rats using the
inﬂammatory model of adjuvant-induced arthritis.47
665Osteoarthritis and Cartilage Vol. 12, No. 8A limiting factor of this study is that due to the demands of
the formal ethics review committee, no healthy human
synovium was investigated, which otherwise might have
represented a negative control for the incubated synovitis
tissue. Apart from ethical concerns, it remains, however,
doubtful whether the key question if also in healthy synovial
tissue up to 30% of PGE2 is generated via the COX-1
pathway could satisfyingly be answered by incubating
synovium from healthy patients. The enormous in vitro
induction of synovial COX-2 due to the tissue preparation
and the long-term incubation itself (>10,000-fold in the
synovitis tissue) would certainly occur in the non-inﬂamed
synovial tissue as well. Accordingly, any data obtained
would not reﬂect the initial in vivo situation of synovial COX-
1 and COX-2 activity. Furthermore, whatever the ratio of
COX-1- and COX-2-dependent PG synthesis may be in
intact, healthy synovium, inﬂamed and not healthy syno-
vium represents the target tissue of COX inhibitors in the
therapy of OA in vivo. It should be noted that with regard to
this target tissue, at least in vitro, our study could
demonstrate a substantial participation of synovial COX-1
in the release of the pro-inﬂammatory eicosanoid PGE2.
The ﬁndings of Iniguez and colleagues, demonstrating
COX-1 to be the abundant isoform in synovial ﬂuid cells in
RA, with a strong immunostaining observed in a special
fraction of mononuclear cells, which was not detectable in
peripheral blood leucocytes (something rather unexpected
for a constitutively expressed housekeeping gene), raise
the question, whether even an induction of COX-1
expression could possibly occur in synovial inﬂammation.13
Additionally, an increased cellularity of inﬂamed synovium,
as has been demonstrated both in RA48 and OA2,3,5 might
subsequently result in elevated levels of COX-1, further
enhancing the synovial PG generation.42 Interestingly,
there is some evidence for a possible, physiological role
of COX-1 in healthy joint capsular tissue, with a yet
unidentiﬁed PG derived via the COX-1 pathway maintaining
the articular perfusion.49
Our study suggests that, at least in vitro, at COX-2-
speciﬁc concentrations, selective COX-2 inhibitors might be
inferior compared to non-selective COX inhibitors in sup-
pressing PGE2 formation in OA synovitis tissue. With res-
pect to the anti-inﬂammatory therapy of OA with selective
COX-2 inhibitors in vivo, the relative contribution of COX-1
in synovitis should be considered, weighing the therapeutic
potency of COX-unspeciﬁc NSAID against the assumed
superior gastrointestinal safety proﬁle of COX-2 inhibitors.
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